An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
LENSAR to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
LENSAR, Inc. (Nasdaq: LNSR) has announced that CEO Nick Curtis will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, with the presentation available on-demand from 7:00 a.m. Eastern Time. The webcast can be accessed through the company's website and will remain available for one month following the event. LENSAR specializes in advanced femtosecond laser surgical solutions for cataracts, aiming to improve surgical outcomes through innovative technology.
Positive
None.
Negative
None.
ORLANDO, Fla.--(BUSINESS WIRE)--
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer will present at the H.C. Wainwright 23rd Annual Global Investment Conference.
Mr. Curtis’ presentation will be available on-demand beginning at 7:00 a.m. Eastern Time on Monday, September 13, 2021 and can be accessed through the Investors section of the Company's website at https://ir.lensar.com. The webcast will be available for one month after the presentation has been posted.
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining better visual outcomes, efficiency and reproducibility by providing advanced imaging, simplified procedure planning, efficient design and precision.
